Latest Regulatory News

Vectus Biosystems has temporarily paused trading of its securities pending a forthcoming announcement, signaling potential material news for investors.

QBE Insurance Group has announced the redemption of its USD 300 million 6.10% fixed rate subordinated notes due 2045, marking a notable step in its capital management strategy with regulatory approval secured.

Biotron Limited is set to acquire Sedarex Limited, gaining global patents for SedRx, a next-generation general anaesthetic, supported by a $2.5 million capital raising to fund regulatory and development milestones.

Bod Science reports a $576k cash outflow in Q1 FY2026 amid ongoing administration and delays in Biortica audit completion. The company plans a shareholder vote in November to approve its acquisition of Biortica and exit from administration.

Pinnacle Minerals Limited has had its trading suspension lifted following a significant announcement about an acquisition and capital raise, signaling renewed momentum for the mining explorer.

Pinnacle Minerals has secured a strategic acquisition of eight critical minerals projects in Idaho and Washington, positioning itself at the forefront of the US critical minerals supply chain. The company also raised $3 million to accelerate exploration and development.

American Uranium has mobilised a drill rig ahead of schedule at its Lo Herma ISR uranium project in Wyoming, aiming to grow and upgrade its existing 8.57 million pound uranium resource through a two-phase drilling campaign.

Tamboran Resources has completed the largest drilling campaign in the Beetaloo Basin, delivering three 10,000-foot lateral wells with record efficiency. The company targets first gas sales by mid-2026, advancing its Northern Territory gas supply ambitions.

ABx Group’s ALCORE subsidiary is advancing its pilot plant infrastructure at Bell Bay, Tasmania, with major equipment designs completed and delivery slated for early 2026.

Pacific Current Group has announced an on-market buy-back of up to 2 million shares, representing nearly 7% of its capital, aiming to enhance earnings per share and capital efficiency.

Eclipse Metals announces plans for a NASDAQ dual listing to boost its rare earth elements strategy and tap into North American capital markets, while maintaining its ASX presence.

Compumedics has secured a $2.15 million placement to fast-track commercialisation of its Somfit D device following early FDA approval, positioning the company for significant growth in the US home sleep testing market.